Its original design capturing the performance of the FN-designed 5.7x28 mm cartridge made it an instant success, and it’s positioned to do it yet again with the dramatic redesign of the FN Five ...

Because of its ability to inform post-resection therapy, assess therapy efficacy, and detect recurrence earlier than standard of care, MRD is rapidly being integrated into clinical trial design ...

Allogene Therapeutics' Q2 2025 update highlights a streamlined ALPHA3 trial, promising ALLO-316 data, and financial discipline.

Context Key Objective Circulating tumor DNA (ctDNA) detection indicates the presence of molecular residual disease (MRD), identifying recurrence earlier than standard approaches. Key roles for ...

Integrating clonoSEQ within OncoEMR simplifies and accelerates access to MRD testing to over 4,500 clinicians across the Flatiron network of 1,000 community-based cancer care locations in the U.S.

AUSTIN, Texas, July 07, 2025--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced data from a colorectal cancer (CRC) study of its tissue-free ...

Pathlight™, the company’s flagship product, is an ultra-sensitive, blood-based, multi-cancer MRD test that is now available for commercial use in the U.S. for patients with breast cancer.